Related Experiment Videos
[What to do with a rising PSA after complete remission post-prostatectomy?]
M Bosset1, J-F Bosset, P Maingon
1Service de Radiothérapie, Centre Georges-François-Leclerc, 1, rue du Professeur-Marion, BP 77980, 21079 Dijon cedex, France. mathieu.bosset@wanadoo.fr
Summary
After radical prostatectomy, 20-40% of patients experience PSA failure. Pelvic irradiation offers curative intent, especially for younger patients with good prognostic factors, while other strategies suit different patient groups.
Area of Science:
- Urology
- Radiation Oncology
- Medical Oncology
Context:
- Radical prostatectomy is a primary treatment for prostate cancer.
- A significant percentage of patients (20-40%) experience biochemical recurrence, defined as isolated PSA failure, post-surgery.
- Management of post-prostatectomy PSA failure requires individualized treatment strategies.
Purpose:
- To outline therapeutic options for isolated PSA failure following radical prostatectomy.
- To delineate patient subgroups and corresponding optimal treatment modalities.
- To provide evidence-based recommendations for managing recurrent prostate cancer after surgery.
Summary:
- Isolated PSA failure post-radical prostatectomy occurs in 20-40% of patients.
- Pelvic irradiation is a curative option, particularly for younger patients with favorable prognostic factors.
- Combined modality treatments (radiation with hormonal or chemotherapy) are considered for patients with poor prognostic factors.
- Hormonotherapy or active surveillance are suitable for patients with limited life expectancy.
Impact:
- Informs clinical decision-making for managing post-prostatectomy PSA recurrence.
- Optimizes treatment selection based on patient age, prognostic factors, and life expectancy.
- Contributes to improved outcomes for prostate cancer survivors experiencing treatment failure.